- Tytuł:
- A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada
- Autorzy:
- Źródło:
- PharmacoEconomics - Open: Healthcare Interventions and Outcomes. 7(2):199-216
Czasopismo naukowe